Management of Endometrial Cancer: Molecular Identikit and Tailored Therapeutic Approach

Ottavia D’Oria1,2, Andrea Giannini2,3,*, Aris Raad Besharat2,4, Donatella Caserta4

1Obstetrics and Gynecological Unit, Department of Woman’s and Child’s Health, San Camillo-Forlanini Hospital, 00152 Rome, Italy
2Department of Medical and Surgical Sciences and Translational Medicine, PhD Course in “Translational Medicine and Oncology”, Sapienza University, 00189 Rome, Italy
3Department of Maternal and Child Health and Urological Sciences, Sapienza University of Rome, Policlinico Umberto I, 00161 Rome, Italy
4Gynecology Division, Department of Medical and Surgical Sciences and Translational Medicine, Sant’Andrea University Hospital, Sapienza University of Rome, 00189 Rome, Italy

*Correspondence: andrea.giannini@uniroma1.it (Andrea Giannini)

Academic Editor: Michael H. Dahan
Submitted: 6 July 2023 Revised: 11 July 2023 Accepted: 14 July 2023 Published: 12 October 2023

Gynecologic oncology management has undergone numerous changes over the past few years. A greater understanding of tumor biology and genetic patterns has changed the therapeutic approach, especially with ovarian and endometrial cancers.

Efforts have focused on improving safety, efficiency, and cost of care in gynecologic oncology.

Endometrial cancer (EC) is the most common gynecological malignancy in developed countries. Considerable progress has recently been made in the management of patients affected by EC, mostly regarding molecular biology and minimally invasive treatment.

90% of patients with EC have abnormal vaginal bleeding as the first main symptom, most frequently during the postmenopausal period, making an early diagnosis possible. Endometrial sampling and imaging based on pelvic Magnetic Resonance Imaging (MRI) are mandatory to provide an accurate diagnosis [1–3].

Pathologic analysis to determine the tumor type and grade, is the standard for tumor risk stratification. Due to a new diagnostic classification centered on molecular and immunohistochemical indicators, the risk classification is much more accurate. On the basis of the outcomes of the Cancer Genome Atlas, and the ProMisE (Proactive Molecular Risk Classifier for EC), tumors are divided into four subgroups according to the presence of polymerase-epsilon (POLE) exonuclease domain mutations (EDMs), and protein 53 (p53) immunohistochemistry and mismatch repair (MMR) proteins, creating four different subgroups: POLEmut, p53 wild type (low copy number–CNL-or non-repair (MMR) proteins, creating four different subgroups: POLE ultramutated and stage IA MMRd/NSMP endometrioid carcinomas, without lymph vascular space invasion (LVSI) [10].

Adjuvant brachytherapy decreases vaginal recurrence in patients with intermediate risk. This category includes patients with stage IB MMRd/NSMP endometrioid carcinomas and low grade, LVSI negative, stage IA MMRd/NSMP endometrioid carcinomas and high grade, no LVSI or focal invasion and stage IA p53abn, and/or non-endometrioid carcinomas [11].

Adjuvant radiotherapy is recommended in the intermediate-high-risk group. This risk group comprises stage IA or IB low-grade endometrioid carcinomas with positive LVSI or stage IB high-grade endometrioid carcinomas unrelated to LVSI, and stage II endometrioid carcinomas [9].

Stage III–IVA MMR-d or NSMP endometrioid carcinomas and stage I–IVA p53abn all-histology or stage IB–IIVA non-endometrioid carcinomas are included in the high-risk group. Because of the high risk of recurrence for patients in this group, post-operative combined chemo-radiotherapy is recommended. Patients who underwent combined therapy (chemo-radiotherapy) showed better overall survival than patients who underwent chemotherapy alone, according to PORTEC-3 trial results [1,12,13].

The molecular biology state creates an EC patient identikit that guides individualized therapeutic approach and follow-up, avoiding overtreatment and improving the...
clinical outcomes of these patients. NCCNNational Comprehensive Cancer Network (NCCN) guidelines identified more risk factors for EC patients: age >60 years, LVSI status, and tumor size, making the identikit even more precise. Studies have also focused on the effect of comorbidities and/or drugs on EC prognosis [14].

Molecular classification can be considered the future standard approach for gynecological cancer management, particularly for endometrial and ovarian cancer, and has avoided unnecessary treatments in patients with good molecular profiles.

Author Contributions
OD and DC designed the research study. AG contributed to the analysis of the data and supervision. AG and ARB wrote the manuscript. All authors contributed to editorial changes in the manuscript. All authors read and approved the final manuscript.

Ethics Approval and Consent to Participate
Not applicable.

Acknowledgment
Not applicable.

Funding
This research received no external funding.

Conflict of Interest
The authors declare no conflict of interest. Andrea Giannini and Donatella Caserta are serving as one of the Editorial Board members of this journal. Ottavia D’Oria, Andrea Giannini and Aris Raad Besharat are serving as one of Guest editors of this journal. We declare that Andrea Giannini, Donatella Caserta, Ottavia D’Oria and Aris Raad Besharat had no involvement in the peer review of this article and has no access to information regarding its peer review. Full responsibility for the editorial process for this article was delegated to Michael H. Dahan.

References